Rating Rationale
October 08, 2020 | Mumbai
Cadila Healthcare Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.3577 Crore
Long Term Rating CRISIL AA+/Stable (Reaffirmed)
Short Term Rating CRISIL A1+ (Reaffirmed)
 
Rs.125 Crore Non Convertible Debentures CRISIL AA+/Stable (Reaffirmed)
Rs.1300 Crore Commercial Paper CRISIL A1+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its ratings on the bank facilities and debt programme of Cadila Healthcare Limited (Cadila Healthcare; a part of the Zydus Cadila group) at 'CRISIL AA+/Stable/CRISIL A1+'.
 
Turnover is expected to sustain 8-9% annual growth over the medium term, led by diversified revenue streams from the US, domestic, emerging markets and consumer wellness division. The contribution from acquired portfolio under the wellness segment is expected to be marginally lower than earlier envisaged on account of sales impact due to Covid-19; however, the segment is expected to ramp up over the medium term. The company's US segment (accounting for 43% of revenue) degrew by 6% in fiscal 2020 largely due to higher base in 2019 because of exclusivity sales. However, the segment is expected to grow 6-7% over the medium term, driven by healthy product pipeline and regular launches. Growth in the US segment may moderate because of warning letter issued in October 2019 on the Moraiya plant (Ahmedabad), which accounts for 35% of the US revenue. Growth in the domestic segment (accounting for 27% of revenue) is expected to moderate in fiscal 2021, given lower prescription-based sales and field visits due to the lockdown. Post-acquisition of Heinz India Pvt Ltd (HIPL), the wellness segment is now the third-largest revenue contributor (accounting for 13% of revenue) of Cadila Healthcare.  
 
The company's operating margin moderated to 19.5% in fiscal 2020 from about 22% in fiscal 2019 due to moderation in the US segment growth. Margin is expected to sustain at 19-20% over the medium term, backed by focus on complex molecules and biosimilars in the domestic and emerging markets, and new product launches in the US market.
   
Financial risk profile is in line with expectation, with gearing at 0.84 time as on March 31, 2020 (0.79 time as on March 31, 2019). In September 2020, there has been equity infusion of Rs 1,000 crores in Zydus Wellness Ltd (Subsidiary; ZWL) with Rs 350 crores from Zydus Family Trust and Rs 650 crore through Qualified Institutional Placement. The proceeds from equity infusion is expected to be utilized for prepayment of debt at ZWL, thereby resulting in debt/EBITDA (earnings before interest, tax, depreciation and amortisation) ratio expected at around 2.2 times in fiscal 2021 against 2.9 times in fiscal 2020, in line with CRISIL's expectations. Large acquisition of HIPL and high goodwill amortisation (CRISIL's analytical adjustment) constrained return on capital employed at ~8% in fiscal 2020 the ratio is expected to improve over the medium term with ramp-up in the consumer wellness division and resolution of the warning letter. Furthermore, debt protection metrics will strengthen as benefits from the acquisition of HIPL accrue, and with progressive annual debt repayment of Rs 800-1,000 crore.
 
The ratings continue to reflect the Zydus Cadila group's growing presence in the international market, particularly the US; established position in the branded generics market in India; the expected benefits from the acquisition of HIPL; and healthy financial risk profile because of adequate debt protection metrics and gearing. These strengths are partially offset by exposure to risks related to unfavourable regulatory changes, increasing competition, and price erosions in the regulated generics markets.

Analytical Approach

For arriving at its ratings of Cadila Healthcare, CRISIL has combined the business and financial risk profiles of Cadila Healthcare and its 40 subsidiaries and step-down subsidiaries (referred to as the Zydus Cadila group) as all these entities operate in the pharmaceutical and related space, with significant operational linkages and a common management. For equal joint ventures (JVs), CRISIL follows a moderate integration approach; specifically, CRISIL factors in share of profit from JVs and share of any incremental investments required by JVs. CRISIL has amortised goodwill consolidated on earlier acquisitions over five years and on HIPL's acquisition over 10 years. Both profit after tax (PAT) and networth are adjusted to that extent.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths
* Established market position
The Zydus Cadila group is the fourth-largest player in the domestic formulations market. It is the leader in the high-growth lifestyle segments such as gastrointestinal, cardiology, respiratory and gynaecology, which account for about 11%, 15%, 11% and 8%, respectively, of its domestic formulation sales. In fiscal 2019, the group strengthened its marketing team by giving more thrust on strategies such as growth in the categories, integration of channel partners, supply chain and procurement to improve revenue and cost synergies. This is reflected in better growth momentum in fiscal 2020, which is expected to sustain over the medium term on the back of established brands, large and therapeutic-focused field force, in-licensing agreements, and product launches. The group also has established presence in Rest of World markets of Brazil, Mexico and South Africa. This segment (including Latin America) grew by about 49% in fiscal 2020, on a lower base. The company also has a healthy pipeline of complex molecules and biosimilars in the domestic and emerging markets, and will be the growth driver over the medium term.
  
* Growing presence in the regulated generics markets
Business prospects are supported by increasing presence in the regulated generics markets such as the US. The group now has 282 approvals and filed 390 abbreviated new drug application (ANDAs), as on March 31, 2020. Healthy pace of filings and approvals in the US, also reflected in the strong ANDA pipeline of over 100 as of March 2020, will strengthen the US business. With formulation revenue of Rs 5,920 crore in fiscal 2020, the group is one of the top 10 players in the US generic market. The warning letter on Moraiya will constrain growth to an extent in the near term, as 8-10 ANDA approvals may be impacted until the remediation and re-inspection is complete; resolution remains a key monitorable.
 
* Healthy financial risk profile
Adjusted gearing and net gearing (net of cash) stood at 0.84 time and 0.71 time, respectively, as on March 31, 2020, and the adjusted gearing is expected at 0.50-0.60 time over the medium term with the equity infusion and prepayment of debt in ZWL. interest coverage ratio will remain at 8-9 times, despite the debt-funded acquisition; however, benefits from the acquisition of HIPL are expected to accrue only over the medium term ' in the interim, debt/EBITDA ratio increased to 2.87 times in fiscal 2020 and is expected to correct to below 2 times over the medium term. Any material debt-funded acquisition or investment in group companies will be a key rating monitorable.
 
Weaknesses
* Exposure to risks related to unfavourable regulatory changes
The Zydus Cadila group remains exposed to regulatory risks, both in the domestic and international markets (particularly the US). For instance, in October 2019, a warning letter was issued for the Moraiya plant. Though the company has prior experience of remediation of warning letter (as in fiscal 2017), timely remediation of the outstanding warning letter will be critical for the future US growth momentum. The ongoing litigation by the anti-trust division of US department of justice on industry generic players regarding price-collusion allegations remains a monitorable. Furthermore, any price-control measures of the Government of India in the branded segment may weaken the domestic formulation growth.
 
* Exposure to intense competition, volatility in foreign exchange (forex) rates, and stretch in working capital cycle
The group faces high competition in regulated markets, where innovator companies engage in aggressive defence tactics by launching authorised generics, and there are several cost-competitive Indian players present. Furthermore, generics players in regulated markets are affected by severe price erosions, given the commoditised nature of products, along with intense competition and considerable government pressure to lower prices. Strong bargaining power of distributors in the US leads to large working capital requirement. Gross current assets remained high at around 230 days as on March 31, 2020. Ample liquidity and high financial flexibility are expected to meet the incremental working capital requirement.
Liquidity Strong

Cash accrual is expected to be over Rs 1,700 crore annually in fiscals 2021 and 2022, and will be sufficient to meet moderate term debt obligation of about Rs 800 crore and 1,000 crore, respectively. Sizeable cash and cash equivalents (including investments in mutual funds) of nearly Rs 1,200 crore as on March 31, 2020, also support liquidity. Besides, the company (standalone) has fund-based bank limit which remained moderately utilised at about 35% for the 12 months period ending March 2020. Cash accrual will be sufficient to meet annual capex of Rs 600-700 crore.

Outlook: Stable

CRISIL believes Cadila Healthcare will maintain a diversified revenue profile across geographies and healthy cash accrual, over the medium term. Financial risk profile is expected to remain strong, with moderate capital expenditure (capex) and gradually improving credit metrics.
 
Rating Sensitivity Factors
Upward Factors 
*Healthy sustained compound annual growth rate of 13-15% in turnover, with increased revenue contribution from the US market following the remediation of warning letter issued by the US Food and Drug Administration (US FDA) or better-than-expected contribution from other manufacturing units
*Sustenance of healthy operating margin at 18-19% supporting adequate cash generation
*Gross debt/EBIDTA of below 2.00 times from about 3.00 times in fiscal 2020
 
Downward Factors    
*Decline in profitability to below 15-16% due to delay in closure of warning letter, increased competition, or weaker-than-expected improvement in HIPL's operations
*Slower-than-anticipated recovery in credit metrics; gross debt/EBITDA increasing to over 3.6-3.8 times owing to lower cash generation, sizeable, debt-funded acquisitions, capital spending, or substantial stretch in working capital cycle.

About the Company

Cadila Laboratories was founded in 1952 by Mr Ramanbhai Patel and Mr Indravadan Modi. Cadila Healthcare came into existence in 1995 following the split of Cadila Laboratories, with the Modi family's share being moved into a new company, Cadila Pharmaceuticals Ltd. The division that was managed by Mr Ramanbhai Patel's son, Mr Pankaj Patel, was renamed Cadila Healthcare, and the group was named the Zydus Cadila group. In 2000, Cadila Healthcare got listed on the Bombay Stock Exchange. Over the years, the company has grown to become one of the top five pharmaceutical entities in India. It also has growing presence in the regulated markets, particularly the US, and is one of the top 10 players in the US generic market. Other segments include emerging markets formulations, consumer wellness, animal healthcare and bulk drugs.
 
As on June 30, 2020, the promoters held 74.88% stake in Cadila Healthcare, 4.56% was held by foreign portfolio investors, and the balance by the public and others.
 
For the first three months of fiscal 2021, the company reported an operating income of Rs 3,640 crore and PAT of Rs 454 crore, against Rs 3,496 crore and Rs 303 crore, respectively, for the corresponding period previous fiscal.

Key Financial Indicators
Particulars Unit 2020 2019
Operating income (net of excise) Rs.Crore 14,253 13,100
Adjusted PAT* Rs.Crore 707 1,383
Adjusted PAT margin* % 5.0 10.6
Adjusted debt/adjusted networth* Times 0.84 0.79
Interest coverage Times 8.6 19
*Adjusted for goodwill and intangibles amortisation

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon Rate (%) Maturity Date Issue Size
(Rs.Cr)
Complexity Level Rating Assigned
with Outlook
NA Bank guarantee NA NA NA 50 NA CRISIL A1+
NA Letter of credit NA NA NA 100 NA CRISIL A1+
NA Cash credit* NA NA NA 1300 NA CRISIL AA+/Stable
NA Long Term Loan NA NA 23-Jan-2024 226.8 NA CRISIL AA+/Stable
NA Long Term Loan NA NA 17-Jan-2022 151.2 NA CRISIL AA+/Stable
NA Long Term Loan NA NA 01-Mar-22 100.8 NA CRISIL AA+/Stable
NA Long Term Loan NA NA 27-Mar-2023 756.0 NA CRISIL AA+/Stable
NA Long term loan NA NA 26-Apr-2022 226.8 NA CRISIL AA+/Stable
NA Long Term Loan NA NA 18-Sep-22 151.2 NA CRISIL AA+/Stable
NA Long term loan NA NA 05-Sep-23 151.2 NA CRISIL AA+/Stable
NA Proposed Long Term Bank Loan Facility NA NA NA 363.0 NA CRISIL AA+/Stable
NA Commercial Paper NA NA 7-365 days 1300.0 Simple CRISIL A1+
NA Non-Convertible Debentures** NA NA NA 75.00 Simple CRISIL AA+/Stable
NA Non-Convertible Debentures** NA NA NA 50.00 Simple CRISIL AA+/Stable
*Fully interchangeable with Working capital demand loan and Packing credit in Foreign Currency
**Yet to be issued
 
Annexure - List of Entities Consolidated
S. No Name of Entity   Extent of Consolidation Rationale of Consolidation
1 Zydus Healthcare Ltd Fully consolidated Subsidiary
2 Zydus Wellness Ltd Fully consolidated Subsidiary
3 Dialforhealth Greencross Ltd Fully consolidated Subsidiary
4 Dialforhealth Unity Ltd Fully consolidated Subsidiary
5 Violio Healthcare Ltd Fully consolidated Subsidiary
6 German Remedies Pharmaceuticals Pvt Ltd
(formerly, Acme Pharmaceuticals Pvt Ltd
Fully consolidated Subsidiary
7 Zydus Wellness Products Ltd (Formerly Zydus Nutritions Ltd) Fully consolidated Subsidiary
8 Liva Nutritions Ltd Fully consolidated Subsidiary
9 Liva Investment Ltd Fully consolidated Subsidiary
10 Zydus Pharmaceuticals Ltd (formerly, Alidac Healthcare Ltd) Fully consolidated Subsidiary
11 Windlas Healthcare Pvt Ltd ' (not a subsidiary as on date) Fully consolidated Subsidiary
12 Zydus Animal Health and Investments Ltd
(formerly, Violio Pharmaceuticals & Investments Ltd)
Fully consolidated Subsidiary
13 Biochem Pharmaceutical Pvt Ltd Fully consolidated Subsidiary
14 Zydus Lanka (Pvt) Ltd (Sri Lanka) Fully consolidated Subsidiary
15 Zydus International Pvt Ltd (Ireland) Fully consolidated Subsidiary
16 Zydus Netherlands B.V. Fully consolidated Subsidiary
17 Zydus France, SAS Fully consolidated Subsidiary
18 Laboratorios Combix S.L. (Spain) Fully consolidated Subsidiary
19 Etna Biotech S.R.L.(Italy) Fully consolidated Subsidiary
20 Zydus Healthcare (USA) LLC Fully consolidated Subsidiary
21 Zydus Pharmaceuticals (USA) Inc.  Fully consolidated Subsidiary
22 Nesher Pharmaceuticals (USA) LLC Fully consolidated Subsidiary
23 Sentynl Therapeutics, Inc (USA) Fully consolidated Subsidiary
24 Zydus Noveltech Inc., (USA) Fully consolidated Subsidiary
25 Hercon Pharmaceuticals, LLC (USA) Fully consolidated Subsidiary
26 ZyVet Animal Health Inc. (USA) Fully consolidated Subsidiary
27 Windlas Inc., (USA) Fully consolidated Subsidiary
28 Viona Pharmaceuticals, LLC (USA) Fully consolidated Subsidiary
29 Zydus Worldwide DMCC (Dubai) Fully consolidated Subsidiary
30 Zydus Discovery DMCC (Dubai) Fully consolidated Subsidiary
31 Zydus Wellness International DMCC (Dubai) Fully consolidated Subsidiary
32 Zydus Nikkho Farmaceutica Ltda. (Brazil) Fully consolidated Subsidiary
33 Zydus Healthcare SA (Pty) Ltd. (South Africa) Fully consolidated Subsidiary
34 Simayla Pharmaceuticals (Pty) Ltd Fully consolidated Subsidiary
35 Script Management Services (Pty) Ltd. Fully consolidated Subsidiary
36 Zydus Healthcare Philippines Inc. Fully consolidated Subsidiary
37 Alidac Healthcare (Myanmar) Ltd Fully consolidated Subsidiary
38 Zydus Pharmaceuticals Mexico SA De CV Fully consolidated Subsidiary
39 Zydus Pharmaceuticals Mexico Service Company SA De CV. Fully consolidated Subsidiary
40 Recon Pharmaceuticals and Investments Fully consolidated Subsidiary
41 Zydus Takeda Healthcare Pvt Ltd (JV) Moderately consolidated Associate
42 Zydus Hospira Oncology Pvt Ltd (JV) Moderately consolidated Associate
43 Bayer Zydus Pharma Pvt Ltd (JV) Moderately consolidated Associate
44 US Pharma Windlas LLC (JV) Moderately consolidated Associate
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Commercial Paper  ST  1300.00  CRISIL A1+  18-09-20  CRISIL A1+  24-12-19  CRISIL A1+  28-12-18  CRISIL A1+    --  -- 
        10-08-20  CRISIL A1+      25-10-18  CRISIL A1+       
                20-09-18  CRISIL A1+       
Non Convertible Debentures  LT  0.00
08-10-20 
CRISIL AA+/Stable  18-09-20  CRISIL AA+/Stable  24-12-19  CRISIL AA+/Stable  28-12-18  CRISIL AA+/Stable  13-06-17  CRISIL AA+/Stable  CRISIL AA+/Stable 
        10-08-20  CRISIL AA+/Stable      25-10-18  CRISIL AA+/Watch Developing  27-01-17  CRISIL AA+/Stable   
                20-09-18  CRISIL AA+/Positive       
                29-06-18  CRISIL AA+/Positive       
Short Term Debt  ST                      CRISIL A1+ 
Short Term Debt (Including Commercial Paper)  ST              29-06-18  CRISIL A1+  13-06-17  CRISIL A1+  -- 
                    27-01-17  CRISIL A1+   
Fund-based Bank Facilities  LT/ST  3427.00  CRISIL AA+/Stable  18-09-20  CRISIL AA+/Stable  24-12-19  CRISIL AA+/Stable  28-12-18  CRISIL AA+/Stable  13-06-17  CRISIL AA+/Stable  CRISIL AA+/Stable 
        10-08-20  CRISIL AA+/Stable      25-10-18  CRISIL AA+/Watch Developing  27-01-17  CRISIL AA+/Stable   
                20-09-18  CRISIL AA+/Positive       
                29-06-18  CRISIL AA+/Positive       
Non Fund-based Bank Facilities  LT/ST  150.00  CRISIL A1+  18-09-20  CRISIL A1+  24-12-19  CRISIL A1+  28-12-18  CRISIL A1+  13-06-17  CRISIL A1+  CRISIL A1+ 
        10-08-20  CRISIL A1+      25-10-18  CRISIL A1+  27-01-17  CRISIL A1+   
                20-09-18  CRISIL A1+       
                29-06-18  CRISIL A1+       
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 50 CRISIL A1+ Bank Guarantee 50 CRISIL A1+
Cash Credit* 1300 CRISIL AA+/Stable Cash Credit* 1300 CRISIL AA+/Stable
Letter of Credit 100 CRISIL A1+ Letter of Credit 100 CRISIL A1+
Long Term Loan 1764 CRISIL AA+/Stable Long Term Loan 1764 CRISIL AA+/Stable
Proposed Long Term Bank Loan Facility 363 CRISIL AA+/Stable Proposed Long Term Bank Loan Facility 363 CRISIL AA+/Stable
Total 3577 -- Total 3577 --
*Fully interchangeable with working capital demand loan and packing credit in foreign currency
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
CRISILs Bank Loan Ratings
CRISILs Criteria for Consolidation
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Anuj Sethi
Senior Director - CRISIL Ratings
CRISIL Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Sameer Charania
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8025
sameer.charania@crisil.com


Abhishek Agarwal
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 4254 3636
Abhishek.Agarwal@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL